Xiaochen Bai Selected Research

Ligands

1/2023

Oncogenic RAS Drives Resistance to Pemigatinib in Cholangiocarcinoma Harboring a FGFR2 Delins Disrupting Ligand Binding.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xiaochen Bai Research Topics

Disease

6	Parkinson Disease (Parkinson's Disease) 01/2021 - 01/2017
1	Cholangiocarcinoma 01/2023
1	Congenital Diaphragmatic Hernias 01/2022
1	Wounds and Injuries (Trauma) 01/2022
1	Neoplasms (Cancer) 10/2021

Drug/Important Bio-Agent (IBA)

5	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 01/2022 - 01/2017
1	pemigatinibIBA 01/2023
1	LigandsIBA 01/2023
1	NeurotoxinsIBA 01/2022
1	Mitogen-Activated Protein KinasesIBA 10/2021
1	Proteins (Proteins, Gene)FDA Link 10/2021
1	ras ProteinsIBA 10/2021
1	fasudil (AT 877)IBA 01/2020
1	regulated endocrine secretory protein 18IBA 01/2018
1	MicroRNAs (MicroRNA)IBA 01/2017

Therapy/Procedure

1	Therapeutics 01/2022
1	Stem Cell Transplantation 01/2020